HK Stock Market Move | PEIJIA-B (09996) rose nearly 3% in the morning of 2024, with a year-on-year increase in revenue of approximately 38.3%-42.8%.

PEIJIA-B (09996) rose by nearly 3% in the morning, and as of the time of writing, it has risen by 2.25% to HK$4.09, with a turnover of HK$61.375 million. In terms of news, PEIJIA-B released its operating data for the fiscal year ending December 31, 2024, with revenue of approximately RMB 610 million to 630 million, representing a year-on-year increase of about 38.3% to 42.8%. The announcement stated that the strong revenue growth was mainly attributed to the continuous rapid growth of all neurointervention product lines of the Group, as well as the expansion of the Group's market share in China's Transcatheter Aortic Valve Replacement (TAVR) market. During the reporting period, significant revenue growth was achieved in neurointervention product lines for bleeding, ischemia, and access routes, due to the increase in surgical penetration rates, the Group's successful bidding in volume purchasing, and its comprehensive product pipeline and effective marketing strategies. Key drivers include the successful launch of the DCwire micro-guidewire nationwide, which has received positive feedback from users and widespread adoption in the market; the further penetration of the Group's existing flagship products, Syphonet retrieval stent and Fastunnel delivery balloon dilation catheter, in the market through differentiated product design and innovative surgical techniques; and the continued adoption of the Group's coil products in volume purchasing due to reliable product quality and brand recognition.